OARS funding Cancer

This limited competition Funding Opportunity Announcement solicits the renewal application for the Chernobyl Tissue Bank Coordinating Center. The Chernobyl Tissue Bank is a collaborative resource that is supported by the National Cancer Institute and another international partner and includes active participation of countries critically affected by the Chernobyl nuclear power plant accident. The objective of the Chernobyl Tissue Bank is to maintain a research resource that supports current and future studies on the biology of thyroid cancer, a major health consequence of the Chernobyl accident. The Chernobyl Tissue Bank Coordinating Center is the critical infrastructure that serves this goal and functions to lead, plan, integrate, and achieve the stated research objectives in collaboration with the participating institutions in the Chernobyl-affected countries.

This limited competition Funding Opportunity Announcement solicits the renewal application for the Chernobyl Tissue Bank Coordinating Center. The Chernobyl Tissue Bank is a collaborative resource that is supported by the National Cancer Institute and another international partner and includes active participation of countries critically affected by the Chernobyl nuclear power plant accident. The objective of the Chernobyl Tissue Bank is to maintain a research resource that supports current and future studies on the biology of thyroid cancer, a major health consequence of the Chernobyl accident. The Chernobyl Tissue Bank Coordinating Center is the critical infrastructure that serves this goal and functions to lead, plan, integrate, and achieve the stated research objectives in collaboration with the participating institutions in the Chernobyl-affected countries.

The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

I-Corps@Ohio is a statewide program to assist faculty and graduate students from Ohio universities and colleges to validate the market potential of their technologies and validate and launch startup companies. I-Corps@Ohio is modeled after the National Science Foundation's (NSF) successful I-Corps program, which is proven to increase innovation, entrepreneurship, and industry collaboration. The I-Corps@Ohio program is an initiative of the Ohio Department of Higher Education.

We are requesting applications for pilot projects that focus on new methods to improve detection of early breast cancer and are especially interested in the development of new techniques in the areas of biological or immunologic methods of early detection. It is our hope that pilot projects will provide preliminary data that leads to applications for more substantial peer-reviewed funding.

Recipients of the award are inspired individuals with projects that show potential to generate new knowledge relating to causes, cure, or treatment of primary brain tumors/brain cancer. The annual award provides up to $600,000 in funding over a four-year period. Over that time, recipients also receive additional support from the foundation through its network of scientists in the field and an annual alumni conference.

Applications to the Fiscal Year 2017 (FY17) Lung Cancer Research Program (LCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The LCRP was initiated in FY09 to promote innovative and competitive research focused on the development of integrated disciplines to identify, treat, and manage early curable lung cancer (excluding mesothelioma).

The Surveillance Research Program (SRP) within the Division of Cancer Control and Population Sciences (DCCPS) and the Prevention, Control and Population Sciences Branch (PCPSB) within the Office of Acquisitions (OA), National Cancer Institute, National Institutes of Health, intends to solicit the Surveillance, Epidemiology, and End Results (SEER) Program.

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity.

 The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

This request for proposals (RFP) is offered by the When Everyone Survives Foundation (WES Foundation) to solicit innovative research in leukemia. Grants of $50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia. The WES Foundation is supporting leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of "when everyone survives".  Renewal of initial research support may be considered for one or more additional years based upon productivity.

This Administrative Supplement funding opportunity announcement is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative. Based on the recommendation to intensify research and form highly dynamic and collaborative networks of investigators to advance our understanding of fusion oncoproteins as drivers of childhood cancers, this FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations to perform research within the scientific scope of the parent grant that will lead to better understanding of the mechanisms of action of fusion oncoproteins as drivers of childhood sarcomas, brain cancers, and high risk leukemias.

This Funding Opportunity Announcement (FOA) invites applications for the development of innovative research projects in cancer nanotechnology. This initiative, to be known as Innovative Research in Cancer Nanotechnology (IRCN), is an integral component of a broader program - the NCI Alliance for Nanotechnology in Cancer (The Alliance) (http://nano.cancer.gov). IRCN awards are designed to enable multi-disciplinary research and transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize fundamental understanding of nanomaterial interactions with biological systems and/or mechanisms of their in vivo delivery.

In 2017, the Pancreatic Cancer Action Network will invest $12.8 million in innovative research related to pancreatic cancer, a 33 percent increase over 2016. This investment includes both the network's competitive, peer-reviewed Research Grants Program and its internal research initiatives. To that end, the network has issued an RFA for its Early Detection Targeted Grant program, through which grants of up to $1 million over four years will be awarded to support ancillary research studies that identify promising blood biomarkers or imaging approaches with the potential to facilitate the use of specimens and/or participants in a cohort of new-onset diabetics and to validate components of a protocol for the early detection of pancreatic ductal adenocarcinoma.

The Foundation encourages all theoretical and experimental research relevant to the study of cancer and the search for cancer causes, mechanisms, therapies and prevention.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status.

TRANSLATIONAL MEDICINE AND THERAPEUTICS: The goal of the PhRMA Foundation's Translational Medicine and Therapeutics Program is to promote the development and use of experimental and computational methods in an integrative approach towards clinical needs in diagnosis, treatment and prevention. This can involve enhanced understanding of human biological and disease processes but requires a strong translational component. This program will support the concepts of Translational Medicine and Therapeutics as defined by the Foundation: "Translational medicine and therapeutics is a discipline focused on bridging experimental and computational technologies and discoveries in the research laboratory to their application in clinical practice. Examples of research components include activities in molecular and cellular biology, pathophysiology, systems biology, bioinformatics, modeling and simulation, and other quantitative sciences to connect basic biological concepts and entities to directly address unmet medical needs. The goals are to use clinical observation as the basis for hypothesis generation to further basic research and to efficiently advance the product of basic research to patients." Translational Medicine and Therapeutics awards will advance training and support career development of scientists engaged in research that significantly integrates cutting-edge technologies with advanced biological, chemical, and pharmacological sciences and engineering methodologies in such areas as (but not restricted to): * Genetics (Molecular, Pharmaco-, Population, Medical) * Genomics (Functional, Structural, Toxico-, Pharmaco-, Comparative) * Systems (Biology and Pharmacology) * Pathways and networks * Integrative biology * Modeling and simulation * Target Identification and Validation * Biomarker Discovery and Validation * Vaccine Development * Molecular Epidimiology * Imaging * Disease Modeling

Alex's Lemonade Stand Foundation, a nonprofit foundation that has evolved from a young cancer patient's front-yard lemonade stand to a national foundation for childhood cancer, awards grants designed to fill critical voids in current pediatric cancer research. Through its Innovation Grants program, the foundation awards two-year grants of up to $250,000 to researchers with a novel approach to pediatric oncology scientific investigation. That can include a change in research direction and/or an innovative new idea that moves away from an investigator's prior research but has potential impact for childhood cancers. Innovation Grants will support research proposals to be carried out by investigators who are already established, have a track record of peer-reviewed publications, and can demonstrate evidence of having successfully competed for extramural funding.

Alex's Lemonade Stand Foundation, a nonprofit foundation that has evolved from a young cancer patient's front-yard lemonade stand to a national foundation for childhood cancer, awards grants designed to fill critical voids in current pediatric cancer research. Through its Innovation Grants program, the foundation awards two-year grants of up to $250,000 to researchers with a novel approach to pediatric oncology scientific investigation. That can include a change in research direction and/or an innovative new idea that moves away from an investigator's prior research but has potential impact for childhood cancers. Innovation Grants will support research proposals to be carried out by investigators who are already established, have a track record of peer-reviewed publications, and can demonstrate evidence of having successfully competed for extramural funding.